Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Mercy Hospital Springfield
mi
from
Springfield, MO
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Mercy Hospital Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cox Medical Center South
mi
from
Springfield, MO
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Nebraska Methodist Hospital
mi
from
Omaha, NE
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Saint Luke's Hospital-Warren Campus
mi
from
Phillipsburg, NJ
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Saint Luke's Hospital-Warren Campus
mi
from
Phillipsburg, NJ
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
University of Cincinnati
mi
from
Cincinnati, OH
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Riverside Methodist Hospital
mi
from
Columbus, OH
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Kettering Medical Center
mi
from
Kettering, OH
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Kettering Medical Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Abington Memorial Hospital
mi
from
Abington, PA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Women and Infants Hospital
mi
from
Providence, RI
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
PeaceHealth Medical Group PC
mi
from
Bellingham, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
PeaceHealth Medical Group PC
mi
from
Bellingham, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Harrison HealthPartners Hematology and Oncology-Bremerton
mi
from
Bremerton, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Harrison HealthPartners Hematology and Oncology-Bremerton
mi
from
Bremerton, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Harrison Medical Center
mi
from
Bremerton, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Harrison Medical Center
mi
from
Bremerton, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Providence Regional Cancer Partnership
mi
from
Everett, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Providence Regional Cancer Partnership
mi
from
Everett, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Skagit Valley Hospital Regional Cancer Care Center
mi
from
Mount Vernon, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Skagit Valley Hospital Regional Cancer Care Center
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Harrison HealthPartners Hematology and Oncology-Poulsbo
mi
from
Poulsbo, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Harrison HealthPartners Hematology and Oncology-Poulsbo
mi
from
Poulsbo, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Pacific Gynecology Specialists
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Pacific Gynecology Specialists
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Group Health Cooperative-Seattle
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Group Health Cooperative-Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Northwest Hospital
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Northwest Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
University of Washington Medical Center
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Olympic Medical Cancer Care Center
mi
from
Sequim, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Olympic Medical Cancer Care Center
mi
from
Sequim, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Rockwood Cancer Treatment Center-DHEC-Downtown
mi
from
Spokane, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Rockwood Cancer Treatment Center-DHEC-Downtown
mi
from
Spokane, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Saint Joseph Medical Center
mi
from
Tacoma, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Saint Joseph Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Providence Saint Mary Regional Cancer Center
mi
from
Walla Walla, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Providence Saint Mary Regional Cancer Center
mi
from
Walla Walla, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Stereotactic Body Radiotherapy for Spine Tumors
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Spine Metastases and Primary Spine Tumors
Status: Enrolling
Updated:  4/20/2016
St. John's Mercy Medical Center
mi
from
St. Louis, MO
Stereotactic Body Radiotherapy for Spine Tumors
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Spine Metastases and Primary Spine Tumors
Status: Enrolling
Updated: 4/20/2016
St. John's Mercy Medical Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Patient and Provider Initiated Survivorship Care Planning
Patient and Provider Initiated Survivorship Care Planning: a Randomized Pilot Study
Status: Enrolling
Updated:  4/20/2016
Sibley Memorial Hospital
mi
from
Washington,
Patient and Provider Initiated Survivorship Care Planning
Patient and Provider Initiated Survivorship Care Planning: a Randomized Pilot Study
Status: Enrolling
Updated: 4/20/2016
Sibley Memorial Hospital
mi
from
Washington,
Click here to add this to my saved trials
Patient and Provider Initiated Survivorship Care Planning
Patient and Provider Initiated Survivorship Care Planning: a Randomized Pilot Study
Status: Enrolling
Updated:  4/20/2016
Suburban Hospital
mi
from
Bethesda, MD
Patient and Provider Initiated Survivorship Care Planning
Patient and Provider Initiated Survivorship Care Planning: a Randomized Pilot Study
Status: Enrolling
Updated: 4/20/2016
Suburban Hospital
mi
from
Bethesda, MD
Click here to add this to my saved trials
Anatomical and Functional Differences Between Continent and Incontinent Men Post Radical Prostatectomy
Status: Enrolling
Updated:  4/20/2016
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Anatomical and Functional Differences Between Continent and Incontinent Men Post Radical Prostatectomy
Status: Enrolling
Updated: 4/20/2016
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Anatomical and Functional Differences Between Continent and Incontinent Men Post Radical Prostatectomy
Status: Enrolling
Updated:  4/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Anatomical and Functional Differences Between Continent and Incontinent Men Post Radical Prostatectomy
Status: Enrolling
Updated: 4/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated:  4/21/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated: 4/21/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated:  4/21/2016
Clinical Research Facility
mi
from
Lafayette, IN
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated: 4/21/2016
Clinical Research Facility
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated:  4/21/2016
Clinical Research Facility
mi
from
New York, NY
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated: 4/21/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated:  4/21/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status: Enrolling
Updated: 4/21/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Symptom Management, Quality of Life and Satisfaction With Care for Advanced Stage Cancers - Control Arm
Symptom Management, Quality of Life and Satisfaction With Care for Advanced Stage Cancers - Control Arm
Status: Enrolling
Updated:  4/21/2016
Lancaster General Ann B. Barshinger Cancer Institute
mi
from
Lancaster, PA
Symptom Management, Quality of Life and Satisfaction With Care for Advanced Stage Cancers - Control Arm
Symptom Management, Quality of Life and Satisfaction With Care for Advanced Stage Cancers - Control Arm
Status: Enrolling
Updated: 4/21/2016
Lancaster General Ann B. Barshinger Cancer Institute
mi
from
Lancaster, PA
Click here to add this to my saved trials
Component and Couple Analysis of Cancer Communications
Component and Couple Analysis of Cancer Communications
Status: Enrolling
Updated:  4/21/2016
The Hartford Hospital
mi
from
Hartford, CT
Component and Couple Analysis of Cancer Communications
Component and Couple Analysis of Cancer Communications
Status: Enrolling
Updated: 4/21/2016
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Component and Couple Analysis of Cancer Communications
Component and Couple Analysis of Cancer Communications
Status: Enrolling
Updated:  4/21/2016
M. D. Anderson
mi
from
Houston, TX
Component and Couple Analysis of Cancer Communications
Component and Couple Analysis of Cancer Communications
Status: Enrolling
Updated: 4/21/2016
M. D. Anderson
mi
from
Houston, TX
Click here to add this to my saved trials